Why the study?
Does nisoldipine compared with enalapril affect cardiovascular outcomes in patients with type 2 diabetes and hypertension?
Does nisoldipine compared with enalapril affect cardiovascular outcomes in patients with type 2 diabetes and hypertension?
In patients with type 2 diabetes and hypertension, nisoldipine was associated with a substantially higher risk of myocardial infarction compared to enalapril, prompting early termination of the therapy.
Enalapril should be prioritized over nisoldipine in type 2 diabetes with hypertension; challenges CCB equivalence and reinforces ACE inhibitor preference.
To the Editor: In 1998 we presented data from the Appropriate Blood Pressure Control in Diabetes (ABCD) trial on the effect of nisoldipine as compared with enalapril on cardiovascular outcomes after five years of follow-up in 470 patients with hypertension and type 2 diabetes.1 The nisoldipine therapy was terminated in the cohort with hypertension on July 14, 1997, as recommended by the study's data and safety monitoring committee. At that time, there had been 25 myocardial infarctions in the nisoldipine group, as compared with 5 myocardial infarctions in the enalapril group, resulting in an unadjusted risk ratio of 5.5 (95 . . .
No takes yet. Share an insight, caveat, or question.
Schrier et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: